BACKGROUND: Reduced bioactive vascular endothelial growth factor (VEGF) has been demonstrated in several inflammatory lung conditions including the acute respiratory distress syndrome (ARDS). sVEGFR-1, a soluble form of VEGF-1 receptor, is a potent natural inhibitor of VEGF. We hypothesised that sVEGFR-1 plays an important role in the regulation of the bioactivity of VEGF within the lung in patients with ARDS. METHODS: Forty one patients with ARDS, 12 at risk of developing ARDS, and 16 normal controls were studied. Bioactive VEGF, total VEGF, and sVEGFR-1 were measured by ELISA in plasma and bronchoalveolar lavage (BAL) fluid. Reverse transcriptase polymerase chain reaction for sVEGFR-1 was performed on BAL cells. RESULTS: sVEGFR-1 was detectable in the BAL fluid of 48% (20/41) of patients with early ARDS (1.4-54.8 ng/ml epithelial lining fluid (ELF)) compared with 8% (1/12) at risk patients (p = 0.017) and none of the normal controls (p = 0.002). By day 4 sVEGFR-1 was detectable in only 2/18 ARDS patients (p = 0.008). Patients with detectable sVEGFR-1 had lower ELF median (IQR) levels of bioactive VEGF than those without detectable sVEGFR-1 (1415.2 (474.9-3192) pg/ml v 4761 (1349-7596.6) pg/ml, median difference 3346 pg/ml (95% CI 305.1 to 14711.9), p = 0.016), but there was no difference in total VEGF levels. BAL cells expressed mRNA for sVEGFR-1 and produced sVEGFR-1 protein which increased following incubation with tumour necrosis factor alpha. CONCLUSION: This study shows for the first time the presence of sVEGFR-1 in the BAL fluid of patients with ARDS. This may explain the presence of reduced bioactive VEGF in patients early in the course of ARDS.
BACKGROUND: Reduced bioactive vascular endothelial growth factor (VEGF) has been demonstrated in several inflammatory lung conditions including the acute respiratory distress syndrome (ARDS). sVEGFR-1, a soluble form of VEGF-1 receptor, is a potent natural inhibitor of VEGF. We hypothesised that sVEGFR-1 plays an important role in the regulation of the bioactivity of VEGF within the lung in patients with ARDS. METHODS: Forty one patients with ARDS, 12 at risk of developing ARDS, and 16 normal controls were studied. Bioactive VEGF, total VEGF, and sVEGFR-1 were measured by ELISA in plasma and bronchoalveolar lavage (BAL) fluid. Reverse transcriptase polymerase chain reaction for sVEGFR-1 was performed on BAL cells. RESULTS: sVEGFR-1 was detectable in the BAL fluid of 48% (20/41) of patients with early ARDS (1.4-54.8 ng/ml epithelial lining fluid (ELF)) compared with 8% (1/12) at risk patients (p = 0.017) and none of the normal controls (p = 0.002). By day 4 sVEGFR-1 was detectable in only 2/18 ARDS patients (p = 0.008). Patients with detectable sVEGFR-1 had lower ELF median (IQR) levels of bioactive VEGF than those without detectable sVEGFR-1 (1415.2 (474.9-3192) pg/ml v 4761 (1349-7596.6) pg/ml, median difference 3346 pg/ml (95% CI 305.1 to 14711.9), p = 0.016), but there was no difference in total VEGF levels. BAL cells expressed mRNA for sVEGFR-1 and produced sVEGFR-1 protein which increased following incubation with tumour necrosis factor alpha. CONCLUSION: This study shows for the first time the presence of sVEGFR-1 in the BAL fluid of patients with ARDS. This may explain the presence of reduced bioactive VEGF in patients early in the course of ARDS.
Authors: Y Kasahara; R M Tuder; L Taraseviciene-Stewart; T D Le Cras; S Abman; P K Hirth; J Waltenberger; N F Voelkel Journal: J Clin Invest Date: 2000-12 Impact factor: 14.808
Authors: W Y Park; R B Goodman; K P Steinberg; J T Ruzinski; F Radella; D R Park; J Pugin; S J Skerrett; L D Hudson; T R Martin Journal: Am J Respir Crit Care Med Date: 2001-11-15 Impact factor: 21.405
Authors: Julia Varet; Samantha K Douglas; Laura Gilmartin; Andrew R L Medford; David O Bates; Steven J Harper; Ann B Millar Journal: Am J Physiol Lung Cell Mol Physiol Date: 2010-03-12 Impact factor: 5.464
Authors: Gavin D Perkins; Nazim Nathani; Alex G Richter; Daniel Park; Murali Shyamsundar; Ritva Heljasvaara; Taina Pihlajaniemi; Mav Manji; W Tunnicliffe; Danny McAuley; Fang Gao; David R Thickett Journal: Crit Care Date: 2009-04-09 Impact factor: 9.097
Authors: Farzad Moazed; Ellen L Burnham; R William Vandivier; Cecilia M O'Kane; Murali Shyamsundar; Umar Hamid; Jason Abbott; David R Thickett; Michael A Matthay; Daniel F McAuley; Carolyn S Calfee Journal: Thorax Date: 2016-02-02 Impact factor: 9.139
Authors: Andrew R L Medford; Samantha K Douglas; Sofia I H Godinho; Kay M Uppington; Lynne Armstrong; Kathleen M Gillespie; Berendine van Zyl; Terry D Tetley; Nassif B N Ibrahim; Ann B Millar Journal: Respir Res Date: 2009-04-09